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Abstract
Background/aims Neuroendocrine tumours occur very rare-
ly in the ampulla of Vater and their clinical behaviour is
unknown. The aim of this study is to assess the clinico-
pathological features, surgical approach and prognosis of
these patients.
Methods Six patients with neuroendocrine tumours of the
ampulla of Vater treated with curative intent surgery at a
single centre were retrospectively analysed. A univariate
analysis of potential prognostic factors was also per-
formed (data provided from the present study and literature
review).
Results Pancreaticoduodenectomy was curative in all the
patients. Overall and disease-free survival rates were signif-
icantly better for G1/G2 tumours (p00.006 and p00.004,
respectively). Although frequent, lymph node metastases
did not influenced both overall (p00.760) and disease-free
survival rates (p00.745). No significant differences of sur-
vival were observed in patients with ENETS stage I/II
disease, as compared to ENETS stage III disease (p00.169
and p00.137, respectively). No differences were observed
according to UICC staging system (p00.073 and p00.177,
respectively). Tumours that are less than 2 cm or limited to
the ampulla appear to have a better prognosis.
Conclusion The WHO 2010 classification appear to accu-
rately predict patient prognosis, while the ENETS or UICC
staging systems have a limited value (especially in regard to
lymph node metastases). Radical surgery (i.e. pancreatico-
duodenectomy with lymphadenectomy) should be the stan-
dard approach in most patients with NET of the ampulla of
Vater because this procedure removes all the potential
tumour-bearing tissue.
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Introduction
Neuroendocrine tumours (NET) of the ampulla of Vater are
considered to be an exceptional pathology. A total of 139
NET of the ampulla of Vater (carcinoids and high-grade
neuroendocrine carcinomas) were identified between 1973
and 2006 in a recent analysis of the Surveillance, Epidemi-
ology and End Results Program of the National Cancer
Institute [1]. To date, data in the literature regarding NET
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of the ampulla of Vater consist only of case reports [2, 3] or
very small case series [4–8].
Currently, there is no standard of care for NET of the
ampulla of Vater [3], mostly due to their poorly defined natural
history [4]. Therapy for these tumours varies from local resec-
tion (endoscopic or surgical ampullectomy) [9–12] to aggres-
sive surgery (i.e. pancreaticoduodenectomy with lymph node
dissection) [4, 5, 13]. The prognostic value of locoregional
lymph node metastasis or other factors, such as depth of
invasion or tumour diameter, are not clearly established [1,
4]. Thus, the question of the best therapeutic approach
remains open.
This study reports a single-centre experience of six patients
diagnosed with NETof the ampulla of Vater, staged according
to the 2010 World Health Organisation (WHO) classification
[14] and tumour-nodes-metastasis (TNM) staging [15, 16]
(Table 1). The clinical and pathological findings and the
surgical treatment of the patients included in the study are
discussed. The relevant literature was reviewed. Furthermore,
an analysis of potential factors influencing survival after
curative intent surgery for NET of the ampulla of Vater was
performed based on data from the present study and available
data from the literature.
Patients and methods
All patients with a final pathological diagnosis of NET of the
ampulla of Vater were retrospectively identified from a pro-
spectively gathered electronic database established at our De-
partment. Between 2002 and 2011 (August 1), 128 patients
with malignant tumours of the ampulla of Vater underwent
pancreaticoduodenectomy at the Center of General Surgery
and Liver Transplantation, Fundeni Clinical Institute, Buchar-
est, Romania. Out of these, 120 tumours were diagnosed as
adenocarcinoma (93.8 %), 2 tumours were diagnosed as gas-
trointestinal stromal tumours (1.62 %) and the remaining 6
patients were diagnosed with NET (4.6 %).
Patient data included age at diagnosis, sex, presenting
symptoms, associated pathology, preoperative imaging and
biopsy results, type of operation, pathology and follow-up
with survival status.
Table 1 Staging systems for NET of the ampulla of Vater: WHO [14], ENETS [16] and UICC [15]
WHO classification
NN grade 1 (low grade) <2 mitoses/10 HPF and<3 % Ki67
NN grade 2 (intermediate grade) 2–20 mitoses/10 HPF or 3 %–20 % Ki67
NC grade 3 (high grade) > 20 mitoses/10 HPF or>20 % Ki67
ENETS staging system UICC staging system
T—primary tumour
Tx Primary tumour cannot be assessed
T0 No evidence of primary tumour
T1 Invasion of lamina propria or submucosa and size≤1 cm Limited to ampulla of Vater or sphincter of Oddi
T2 Invasion of muscularis propria or size>1 cm Invasion of the duodenum wall
T3 Invasion of the pancreas or retroperitoneum Invasion of the pancreas
T4 Invasion of the peritoneum or other organs Invasion in peripancreatic soft tissues or other adjacent organs or structures
N—regional lymph nodes
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis present
M—distant metastasis
Mx Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis present
Staging Stage I T1 N0 M0 Stage Ia T1 N0 M0
Stage IIa T2 N0 M0 Stage Ib T2 N0 M0
Stage IIb T3 N0 M0 Stage IIa T3 N0 M0
Stage IIIa T4 N0 M0 Stage IIb T1,2,3 N1 M0
Stage IIIb Any T N1 M0 Stage III T4 Any N M0
Stage IV Any T Any N M1 Stage IV Any T Any N M1
WHO World Health Organisation classification, ENETS European Neuroendocrine Tumour Society staging system, UICC International Union
Against Cancer staging system, NN neuroendocrine neoplasm, NC neuroendocrine carcinoma, HPF high power fields
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Computed tomography (CT) and/or a magnetic reso-
nance imaging (MRI) were the main preoperative imaging
work-up modalities, with the aim of characterizing the tu-
mour and assessing the presence of involved locoregional
lymph nodes or distant metastases.
The pathological data were assessed by the same patholo-
gist (VH), considering the WHO 2010 classification, the
European Neuroendocrine Tumour Society (ENETS) and In-
ternational Union Against Cancer (UICC) staging systems.
All the tumours were immunostained for chromogranin A,
synaptophysin and neuron-specific enolase to confirm the
diagnosis of NET. For grading, the Ki67 index was assessed
using the MIB1 antibody as a percent of 2,000 tumour cells in
areas where the highest nuclear labelling was noticed.
Follow-up protocol after surgery included clinical exami-
nation and CT or MRI every 3 months in the first year and
every 6 months after the first year.
Survival analysis
Because the number of the patients in the present series was
too small to perform a survival analysis and to assess the
potential factors influencing the long-term outcome after cu-
rative intent surgery for NET of the ampulla of Vater, we
searched the literature for additional available data (i.e.
WHO classification, ENETS and UICC staging systems, tu-
mour diameter, T stage, lymph node involvement, survival
status, overall and disease-free survival). A total of 37 patients
who underwent pancreaticoduodenectomy for NET of the
ampulla of Vater were introduced in a univariate analysis,
including our cases (Table 2) [4, 5, 8, 17–21].
Statistical analysis
Numeric data are expressed as median (range). Survival
curves were estimated using the Kaplan–Meier method and
were compared using the log-rank test. A p value<0.05 was
considered to be statistically significant.
Results
Patient demographics and preoperative work-up
The patients were predominantly male (male/female ratio0
4:2), with a median age of 54 years (range, 32–68 years). The
main presenting symptom was jaundice (four patients), while
two patients presented with epigastric pain. Five patients
presented with cholestasis syndrome (minor cholestasis in
one patient, major cholestasis in four patients). In the patients
with jaundice, the total bilirubin level ranged from 3.0 to
17.0 mg/dl (median 13 mg/dl). No patient had anaemia.
Preoperative imaging included CT (two patients), MRI
(three patients) or both (one patient). The CT and/or MRI
showed the ampullary tumour in all cases; in patients with
cholestasis syndrome, on noticed dilatation of the intra- and
extrahepatic bile ducts, along with dilatation of Wirsung's
duct (Fig. 1a). No distant metastases to the liver, lung, perito-
neum or other organs were observed. Enlarged locoregional
lymph nodes were observed in one patient on preoperative
imaging.
Endoscopic ultrasound was performed on one patient,
showing a hypoechoic tumour mass at the level of the
ampulla of Vater (0.8 cm, not invading the muscularis
propria), with secondary dilatation of the common bile duct
and Wirsung's duct. No enlarged lymph nodes were detected
(Fig. 1c).
Upper endoscopy with biopsy was performed in four
patients. Preoperative tumour biopsy diagnosed a NET in
three patients; in one patient, although malignancy was
suspected, it was not possible to differentiate the tumour
histopathologically. Endoscopic retrograde cholangiogra-
phy was performed in one patient, showing a dilated
common bile duct with distal stenosis (Fig. 1b). None of
the patients had symptoms of an endocrine hypersecretion
syndrome, but one patient had associated neurofibromatosis
(von Recklinghausen's disease).
Operative treatment and pathological findings
All the patients were treated with pylorus-preserving pan-
creaticoduodenectomy, with nil mortality. All the operative
specimens were assessed as R0 resections (without micro-
scopic residual tumour). Median size of the tumour was
1.25 cm (range, 0.8 to 2 cm). All of the tumours were
found to be diffusely positive for chromogranin A, synapto-
physin and neuron-specific enolase with immunohistochem-
istry, confirming their neuroendocrine origin. The Ki67 index
was≤2 % in three tumours, 3–20 % in one tumour and>20 %
in two tumours.
The median number of harvested lymph nodes was 15
(range, 10–19). Locoregional lymph node metastases were
observed in four patients. Lymph node ratio (i.e. ratio of
positive to excised lymph nodes) ranged from 0.06 to 0.68.
The presence of lymph node metastases was assessed by
histopathological examination using hematoxylin-eosin stain-
ing (Fig. 1d).
Tumours assessments according to the ENETS, UICC
staging systems and the WHO 2010 classification are shown
in Table 2.
Follow-up and survival status
Complete follow-up data were available for all patients, as
shown in Table 2. No patient had adjuvant chemotherapy. At
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the last follow-up (November 1, 2011), five patients were
alive and disease-free, while one patient died at 24 months
after surgery with liver metastases. Interestingly, the deceased
patient's tumour was assessed as a stage I tumour according to
ENETS/UICC TNM classification (1-cm tumour size, con-
fined to the submucosa and no lymph node metastases),
although it was a high-grade neuroendocrine carcinoma.
Factors influencing long-term survival after curative intent
surgery (i.e. pancreaticoduodenectomy) for NETof the ampulla
of Vater (present study and data from the literature)
Patients included in the survival analysis had the following
features (Table 2): G3 neuroendocrine carcinoma was found
in 17 patients (63 %) and G1/G2 neuroendocrine neoplasms
Table 2 Data of 37 patients with pancreaticoduodenectomy for NET of the ampulla of Vater, taken into consideration for survival analysis
No Reference WHO ENETS UICC D T (ENETS) N DFS OS Status
1 Nassar H et al. [8] NC G3 IIIb IIb – – N1 24 30 Dead
2 Nassar H et al. [8] NC G3 IIIb IIb – – N1 10 13 Dead
3 Nassar H et al. [8] NC G3 IIIb IIb – – N1 17 17 Alive
4 Nassar H et al. [8] NC G3 IIIb III – – N1 10 16 Dead
5 Nassar H et al. [8] NC G3 IIIb III – – N1 10 10 Alive
6 Nassar H et al. [8] NC G3 IIIb III – – N1 2 4 Dead
7 Nassar H et al. [8] NC G3 IIb IIa – – N0 48 48 Alive
8 Nassar H et al. [8] NC G3 IIb Ib – – N0 6 6 Alive
9 Carter JT et al. [4] NC G3 IIIb IIb 3.5 T3 N1 10 15 Dead
10 Carter JT et al. [4] NT G1/G2 IIIb IIb 1 T1 N1 48 48 Alive
11 Carter JT et al. [4] NT G1/G2 IIIb IIb 1.6 T2 N1 31 31 Alive
12 Carter JT et al. [4] NT G1/G2 IIa Ia 2.5 T2 N0 25 25 Alive
13 Carter JT et al. [4] NT G1/G2 IIIb IIb 2.1 T2 N1 19 19 Alive
14 Hwang S et al. [5] – IIIa Ib 2 T4 N0 6 9 Dead
15 Hwang S et al. [5] – IIIa IIa 2.3 T4 N0 6 16 Dead
16 Hwang S et al. [5] – I Ia 1 T1 N0 37 42 Dead
17 Hwang S et al. [5] – IIIa IIa 3.5 T4 N0 31 31 Dead
18 Hwang S et al. [5] – IIIb IIb 5 T4 N1 30 44 Alive
19 Hwang S et al. [5] – IIa Ia 1.6 T2 N0 38 38 Alive
20 Hwang S et al. [5] – I Ia 1 T1 N0 35 35 Alive
21 Hwang S et al. [5] – I Ia 0.7 T1 N0 29 29 Alive
22 Hwang S et al. [5] – IIIb IIb 1.5 T2 N1 21 21 Alive
23 Hwang S et al. [5] – IIIa Ib 2.7 T4 N0 13 20 Alive
24 Selvakumar E et al. [19] NT G1 – – – – – 24 24 Alive
25 Selvakumar E et al. [19] NC G3 – – – – – 9 13 Dead
26 Selvakumar E et al. [19] NC G3 – – – – – 7 11 Dead
27 Selvakumar E et al. [19] NC G3 – – – – – 4 7 Dead
28 Cavazza A et al. [17] NC G3 IIIb IIb 3 T3 N1 2 8 Dead
29 Stojsic Z et al. [21] NC G3 IIIb IIb 3 T2 N1 2 11 Alive
30 Huang S et al. [18] NC G3 IIIb IIb 2.8 T3 N1 5 10 Dead
31 Senda E et al. [20] NT G2 IIIb IIb 0.7 T2 N1 24 24 Alive
32 Present study NT G2 IIIb IIb 0.8 T1 N1 80 80 Alive
33 Present study NC G3 I Ia 1 T1 N0 18 24 Dead
34 Present study NC G3 IIIb IIb 1.5 T2 N1 52 52 Alive
35 Present study NT G1 IIa Ia 2 T2 N0 32 32 Alive
36 Present study NT G1 IIIb IIb 2 T3 N1 6 6 Alive
37 Present study NT G1 IIIb IIb 1 T1 N1 4 4 Alive
WHO World Health Organisation classification, ENETS European Neuroendocrine Tumour Society staging system, UICC International Union
Against Cancer staging system, D tumour maximal diameter (cm), T tumour status, N locoregional lymph nodes status, DFS disease-free survival
(months), OS overall survival (months), NT neuroendocrine tumour, NC neuroendocrine carcinoma
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were found in 10 patients. Twenty patients had lymph node
metastases (60 %) and 13 patients had negative lymph
nodes. Tumours were limited to the ampulla (T1/T2
ENETS) in 15 patients (60 %) and were locally invasive
(T3/T4 ENETS) in 10 patients. Tumour diameter was <2 cm
in 12 patients (48 %) and was ≥2 cm in 13 patients. ENETS
stage III disease was found in 24 patients (73 %) and
ENETS stages I and II disease was found in 9 patients.
UICC stage III disease was found in 3 patients, while UICC
stage I and II diseases were found in 8 patients and 22
patients (66 %), respectively.
WHO classification was found to be a significant factor for
predicting both overall and disease-free survival (Table 3), as
shown in Fig. 2a, b. Interestingly, there were no significant
differences in terms of overall and disease-free survival in
patients with lymph node metastases, as compared with
patients who had negative lymph nodes (Table 3). Depth of
the tumour invasion (T status) appeared to be a significant
factor influencing overall and disease-free survival (Table 3),
as shown in Fig. 3a, b. Regarding tumour diameter, the overall
and disease-free median survival for patients with tumours
<2 cm was significantly higher than in patients with tumours
≥2 cm (Table 3), as shown in Fig. 3c, d. There were no
significant differences in overall and disease-free survival
among patients with ENETS stage I/II vs. stage III disease
(Table 3), as shown in Fig. 4a, b. No differences of both overall
and disease-free survival rates were observed between patients
with UICC stages I, II and III (Table 3), as shown in Fig. 4c, d.
Discussions
Although NET (initially assessed as carcinoid tumour) was
first described over 100 years ago at the University of
Munich by Siegfried Oberndorfer, these tumours still raise
many issues regarding classification, prognosis and choice
of the best therapeutic approach [22].
The incidence and prevalence of NET seems to have
increased in recent years, most likely due to an improvement
in diagnostic techniques [23, 24]. However, among gastro-
enteropancreatic NET, the ampulla of Vater represents an
uncommon site for the disease [23]. Nevertheless, the num-
ber of papers addressing the ampulla of Vater NET seems to
have increased in recent years [1, 4–6, 19]. Thus, the choice
of an optimal approach for this pathology remains difficult.
Gastroenteropancreatic NET are, by far, less frequent
than adenocarcinomas [24], a statement that is also true for
NET of the ampulla of Vater [19, 25]. In a recent analysis of
450 patients with ampullary neoplasms resected at Johns
Hopkins, none of the tumours were diagnosed as neuro-
endocrine [26]. Other series reported an incidence of NET
that ranged from less than 1 to 8.8 % (of all patients
Fig. 1 a Magnetic resonance
cholangiopancreatography
showing an ampullary soft tissue
mass (T), with secondary
dilatation of the common bile
duct (c) and main pancreatic duct
(arrow head); b endoscopic
retrograde
cholangiopancreatography
showing an irregular, fusiform
stenosis of the common bile duct
toward the ampulla of Vater, with
secondary dilatation; c
endoscopic ultrasound revealing
the ampulla with a 8×7 mm
hypoechoic lesion (T), not
invading the muscularis propria
and with secondary dilatation of
the common bile duct (c) and




metastases into a locoregional
lymph node of a G1
neuroendocrine neoplasm—
nests of uniforms, polygonal
tumour cells with round nuclei
and “salt and pepper” chromatin
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undergoing resections of malignant tumours of the ampulla of
Vater) [1, 5, 19, 25].
CT, MRI, ultrasound endoscopy and endoscopic retrograde
cholangiopancreatography with biopsy are the main tools for
preoperatively assessing NET of the ampulla of Vater [3].
Accuracy rates of biopsy for the preoperative diagnosis of
NET range from to 14 to 66 % [3–6]. In this series, a correct
diagnosis of a NET was established preoperatively in three
patients (out of the four patients who had a preoperative
biopsy). Thus, the preoperative diagnostic accuracy was 75 %.
Currently, several options are available to treat NET of
the ampulla of Vater. Endoscopic local resection and surgi-
cal ampullectomy have been considered to be safe for small
NET of the ampulla of Vater (less than 2 cm) [27] or in
patients with severe comorbidities [3]. Endoscopic ampul-
lectomy is considered to be safe only in very selected cases
Fig. 2 Overall (a) and disease-free (b) survival curves according to WHO classification for 27 patients undergoing pancreaticoduodenectomy for
NET of the ampulla of Vater
Table 3 Univariate predictors
of overall and disease-free
survival in patients with
pancreaticoduodenectomy for
NET of the ampulla of Vater








aData for median survival were
not available because all of the
patients in the G1/G2 group
were censored
Median OS (months) P value Median DFS (months) P value
WHO classification
G1/G2 NAa 0.006 NAa 0.004
G3 NAa NAa
Lymph nodes
N0 42 0.760, ns 37 0.0745, ns
N1 50 50
ENETS
T1/T2 63 0.008 63 0.004
T3/T4 22 17
Tumour diameter
<2 cm 65 0.030 66 0.032
≥2 cm 27 23
ENETS stage
Stage I/II 42 0.169, ns 41 0.137, ns
Stage III 45 43
UICC stage
Stage I 42 0.073, ns 37 0.177, ns
Stage II 51 49
Stage III 16 10
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of well-differentiated NET (T1 N0, negative resection
margins, Ki67 <2 %) [12]. A major limitation of these
procedures is the inability to address locoregional lymph
node metastases, possibly leading to an inadequate onco-
logical operation and potentially jeopardizing the patient's
prognosis [28].
Pancreaticoduodenectomy has been generally considered
the procedure of choice for NET of the ampulla of Vater that
are larger than 2 cm and for cases of neuroendocrine carci-
nomas [3, 6]. In a review of 105 reported cases from the
literature, pancreaticoduodenectomy was performed in more
than 50 % of the patients [3]; a preference for this surgical
Fig. 3 Overall (a) and disease-free (b) survival curves according to
local invasiveness of the tumour for 25 patients undergoing pancreati-
coduodenectomy for NET of the ampulla of Vater (tumours limited to
ampulla—T1/T2 vs. local invasive tumours—T3/T4); overall (c) and
disease-free (d) survival curves according to tumour diameter for 25
patients undergoing pancreaticoduodenectomy for NET of the ampulla
of Vater (<2 cm vs. ≥2 cm)
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approach was also noticed in the most recent reported series
[4–6]. In a recent multi-institutional review of patients with
resected small neuroendocrine pancreatic and periampullary
NET, local resection had similar results to pancreaticoduode-
nectomy in terms of overall survival but was associated with
significantly lower morbidity [29]. Similar data were reported
by previous studies [30]. However, this study addressed a
selected group of patients (with tumours less than 3 cm and
no involved lymph nodes or liver metastases) [29]. Moreover,
in experienced centres, the morbidity and mortality rates of the
transduodenal local excision of ampullary lesions are compa-
rable to pancreaticoduodenectomy [31].
In clinical practice, it is impossible to differentiate a
neuroendocrine neoplasm from a neuroendocrine carcinoma
Figure 4 Overall (a) and disease-free (b) survival curves according to
ENETS staging system for 33 patients undergoing pancreaticoduode-
nectomy for NET of the ampulla of Vater (stage I/II vs. stage III);
overall (c) and disease-free (d) survival curves according to UICC
staging system for 33 patients undergoing pancreaticoduodenectomy
for NET of the ampulla of Vater (stage I vs. II vs. stage III)
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intraoperatively. Sometimes, it is very difficult to differen-
tiate NET from an adenocarcinoma of the ampulla of Vater
on frozen sections [3]. Moreover, preoperative imaging
tools or intraoperative exploration may not identify liver
metastases that are smaller than 0.5 cm or lymph node
metastases [24]. The lack of an accurate assessment of small
liver or lymph node metastases may jeopardize the choice
for an adequate surgical approach.
A question that arises is: does the therapeutic approach to
the NET of the ampulla of Vater have the same principles of
adenocarcinoma? Pancreaticoduodenectomy represents the
procedure of choice for adenocarcinoma of the ampulla of
Vater [26] and has proved to be curative in the majority of
patients without lymph node metastases [32]. Ampullectomy
is recommended only in highly selected cases—Tis/T1 N0,
G1—G2 tumours [25, 28]. Moreover, even in T1 tumours, the
rate of lymph node metastases is approximately 10 %; thus, in
patients with a pTis or pT1 carcinoma, ampullectomy should
be accomplished by a local lymph node dissection to ensure
an oncological resection [25].
For ampullary adenocarcinomas, the presence of metasta-
ses in locoregional lymph nodes is a poor prognostic factor
that is encountered in 47 to 65 % of the resected patients [25,
26, 28, 32]. An increased rate of metastases in the locoregional
lymph nodes (up to 80 %) was also observed in patients with
NET of the ampulla of Vater resected by pancreaticoduode-
nectomy, especially in patients with high-grade carcinomas [1,
8], but no correlation with survival was found [4, 6]. Interest-
ingly, even in small tumours (less than 2 cm), the presence of
lymph node metastases is higher than 50 % [4, 7, 30, 33].
However, a recent study from Asan Medical Center showed
an incidence of positive lymph nodes of only 20 % after
curative intent resection of NET of the ampulla of Vater [5].
In this series of patients, a high incidence of locoregional
lymph node metastases was observed, although none of the
tumours were larger than 2 cm (median size—1.25 cm). How-
ever, no correlation with survival was identified for the in-
volved lymph nodes. The four patients with histologically
proven positive lymph nodes survived without recurrence
for up to 80 months, while a patient without lymph node
metastases died 2 years after surgery with recurrent disease
in the liver. Interestingly, preoperative imaging failed to detect
metastases in the locoregional lymph nodes in most patients
and in patients with pathologically confirmed lymph node
metastases; intraoperative exploration did not show macro-
scopically enlarged lymph nodes. Conversely, the enlarged
lymph nodes detected on preoperative CT in one patient were
not pathologically confirmed as metastases. The same features
were reported by other studies [4].
In summary, although an increased rate of positive lymph
nodes was reported in both adenocarcinomas and NET of
the ampulla of Vater, the clinical impact of this finding
appears to be different in the two pathologies.
Assessment of prognosis is another important issue for
NET of the ampulla of Vater. NET of the ampulla of Vater
has a very similar prognosis to the prognosis of gastroenter-
opancreatic NET in general, with a 5-year survival rate of
approximately 70 % [7]. Some studies reported a worse
prognosis for NET of the ampulla of Vater compared to
duodenal NET [33]. According to data from the Surveil-
lance, Epidemiology and End Results Program, survival
rates at 5 and 10 years are 82 and 71 % for NET, respec-
tively, while for high-grade neuroendocrine carcinomas of
the ampulla of Vater, the prognosis is significantly worse
(15 % at 5 and 10 years) [1, 8]. The recurrence rate is
approximately 40 to 50 % [3, 5], with the liver being the
most common site of initial metastases [5].
Assessment of prognosis in patients with NET of the
ampulla of Vater is difficult due to the small number of
patients reported in the literature [3]. The most widely used
classification was proposed by UICC [15]. In 2010, the
WHO proposed a new pathological classification for gastro-
enteropancreatic NET [14] and the ENETS previously
(2006) proposed a grading system along with a TNM stag-
ing [16]. The main goal of these classifications was to better
assess the prognosis of patients with different tumour locations.
Although ENETS provides a TNM staging system for NET of
the ampulla of Vater [16], its clinical value is unknown because
there are no large series of patients to provide survival data.
In the present study, tumour grading (WHO 2010) clas-
sification seems to accurately predict the prognosis of
patients with NET of the ampulla of Vater, while the ENETS
or UICC staging systems does not appear to be correlated
with survival. Previous studies showed that the ENETS
staging system is not a good predictor of prognosis for
patients with NET of the ampulla of Vater [4]; however,
high-grade neuroendocrine carcinoma has been associated
with a poor prognosis and a median survival between 10.3
and 14.5 months [1, 6, 8, 19]. Thus, an advanced TNM stage
is not necessarily correlated with a worse survival rate. The
present study showed a correlation of the tumour size with
the recurrence rate and overall survival, contrary to data
from previous studies [34]. Tumour diameter (more than
2 cm) and tumour extension beyond the ampulla were also
found to be associated with a high risk for recurrence upon
univariate analysis in a recent study [5]. Although certain
factors, such as younger age [1, 6], small tumour size [1, 6,
8] and the presence of type I neurofibromatosis [1] seem to
be more frequent in patients with G1/G2 NETof the ampulla
of Vater, these data cannot be used in clinical decision
making. Angiolymphatic, perineural or venous invasion
was recently found to be more frequent in high-grade
carcinomas, but no correlation with survival was dem-
onstrated [6].
The analysis performed in the present paper showed
that the presence of positive locoregional lymph nodes has
Langenbecks Arch Surg (2012) 397:933–943 941
no impact on overall or disease-free survival. This feature
may explain the previously reported good oncological
results obtained with local resection of NET of the
ampulla of Vater [29, 30]. The only factors that seem
to be negatively correlated with patient prognosis upon uni-
variate analysis are local invasiveness of the tumour (into the
pancreas, retroperitoneum, serosa and other adjacent organs),
large tumours (over 2 cm) and high-grade/G3 neuroendocrine
carcinoma.
The present study has some limitations. First, the survival
analysis is limited by the small number of patients, precluding
a multivariate analysis. Furthermore, a relatively large number
of patients had high-grade neuroendocrine carcinomas, a fea-
ture that could explain a worse long-term prognosis (com-
pared to previous reports) [1, 7]. The retrospective design of
this study may be associated with problems in data collection.
Additionally, heterogeneity in the follow-up of the patients
included in the survival analysis may be a confounding factor,
mainly in regard to the long-term estimates of disease-free and
overall survival.
Conclusions
Although NET of the ampulla of Vater represents a rare
pathology, it has been increasingly reported in the last years.
The WHO classification seems to accurately predict prog-
nosis, while the ENETS or UICC staging systems have
limited value (especially in regard to lymph node metastases).
However, NET limited to the ampulla of Vater (without local
invasion) seems to have a better prognosis, as do tumours
smaller than 2 cm.
Radical surgery (i.e. pancreaticoduodenectomy) should
be the standard approach in most patients with NET of the
ampulla of Vater, due to the high incidence and poor accu-
racy of preoperative and intraoperative assessments of
lymph node metastases. The low accuracy of preoperative
biopsies in the diagnosis of NET and the difficulty of dif-
ferentiating NET from adenocarcinomas by frozen section
analysis are also strong arguments for an aggressive surgical
approach.
Although the overall and disease-free survival rates do
not appear to be influenced by the presence of lymph node
metastases, locoregional lymphadenectomy should be per-
formed routinely because this procedure removes all the
potential tumour-bearing tissue.
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